This Week in Digital Health’s Post

Eisai US have continued on their streak of promising investments coming into 2024, having announced that they will be working with ANGLE on a phase II HER2 oncology drug, using ANGLE's unique diagnostic technology. The deal is worth about $250,000 and will open the door for further work together down the line, should the trial prove successful. The pilot study will test the capabilities of ANGLE's unique approach, and will hopefully lead to multiple follow up studies into a cancer type that makes up 55% of all breast cancer cases! Follow Warman O'Brien for all the latest updates in the life sciences industry! #pharmaceutical #goodnews #biotech #lifesciences

✨ 𝗣𝗳𝗶𝘇𝗲𝗿 𝗘𝘅𝗽𝗮𝗻𝗱𝘀 𝗖𝗮𝗻𝗰𝗲𝗿 𝗧𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗣𝗶𝗽𝗲𝗹𝗶𝗻𝗲 𝘄𝗶𝘁𝗵 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝘃𝗲 𝗔𝗻𝘁𝗶𝗯𝗼𝗱𝘆-𝗗𝗿𝘂𝗴 𝗖𝗼𝗻𝗷𝘂𝗴𝗮𝘁𝗲𝘀 𝗧𝗵𝗲𝗿𝗮𝗽𝘆 𝗜𝗻𝘃𝗲𝘀𝘁𝗺𝗲𝗻𝘁! 𝗜𝗻 𝗙𝗲𝗯𝗿𝘂𝗮𝗿𝘆 𝟮𝟬𝟮𝟰, 🕬 Pfizer is turning to focus on #cancer , with a laser focus on next-generation #antibodydrugconjugates (ADCs), small #molecules💊, and bispecific antibodies, following significant investments in #covid19 -19 🞿 during the past few years. Pfizer now has 60 cancer initiatives, quadruple its previous level. Pfizer has 🚨 refocused its efforts on four primary cancer categories: hematology-oncology, which includes multiple #myeloma💉and #lymphomas; genitourinary cancer, which includes prostate and urothelial cancers; and #thoracic cancers, including #lung, #head, and #neck cancers. Using three different modalities—small compounds, ADCs, and bispecific antibodies—as well as additional immuno-oncology biologics💉💅, the pharma giant is currently investigating 🔬 the four main areas. With the use of Seagen's ADC technology and Pfizer's protein engineering and 🟂antibody design skills, the company's next-generation ADC platform allows it to target new targets🖸 and create better, more distinctive payloads. 𝗕𝗿𝗼𝘄𝘀𝗲 𝗮𝘁 𝗼𝘂𝗿 𝗟𝗶𝗻𝗸𝗲𝗱 𝗥𝗲𝗽𝗼𝗿𝘁 👉: https://bit.ly/3UZP4Wg #pfizer   #oncology #multiplemyeloma  #rarediseases #genetherapy #proteinengineering #prophecymarketinsights

Antibody drug conjugates (ADCs) the emerging platform for undruggable cancers and hard-to-treat diseases Jul 2024 Worldwide sales of ADCs $7.5 billion in 2022. Estimated more than $30 billion by 2028, CAGR 25%. Currently, there are 12 FDA approved ADCs, covering 16 indications, including several types of breast cancer, non-small-cell lung cancer, bladder cancer, classic and non-Hodgkin lymphoma and more. Emerging pharma is driving the vast majority of ADC development. It can be attributed to Clinical improvement, Commercial potential, De-risked development and Platform potential #antibodydrugconjugates #monoclonalantibodies #cancertreatment #clinicaltrials #researchanddevelopment #innovation #healthcare #lifesciences #biotechnology #pharmaceuticals

eFFECTOR Therapeutics, Inc. said it will halt development of tomivosertib in #lungcancer after the MNK inhibitor failed to significantly improve survival. https://lnkd.in/d3cMqd4y #biotechnology #cancer #clinicalresearch #clinicaltrials #drugdevelopment #oncology #pharmaceuticals

#AntiBodyConjugates (#ADC) trials by phase and #Tumor type

New Drugs on the Horizon sessions feature first disclosures of 12 new anticancer therapies This year's three New Drugs on the Horizon sessions featured first disclosures on the structure, mechanism of action, and functional target modulation of 12 novel cancer agents

𝗜𝗼𝗻𝗶𝘇𝗮𝗯𝗹𝗲 𝗗𝗿𝘂𝗴𝘀 𝗘𝗻𝗮𝗯𝗹𝗲 𝗜𝗻𝘁𝗿𝗮𝗰𝗲𝗹𝗹𝘂𝗹𝗮𝗿 𝗗𝗲𝗹𝗶𝘃𝗲𝗿𝘆 𝗼𝗳 𝗖𝗼-𝗙𝗼𝗿𝗺𝘂𝗹𝗮𝘁𝗲𝗱 𝘀𝗶𝗥𝗡𝗔. Targeting complementary pathways in diseases such as cancer can be achieved with co-delivery of small interfering ribonucleic acid (siRNA) and small molecule drugs; however, current formulation strategies are typically limited to one, but not both. Here, ionizable small-molecule drugs and siRNA are co-formulated in drug-rich nanoparticles. Ionizable analogs of the selective estrogen receptor degrader fulvestrant self-assemble into colloidal drug aggregates and cause endosomal disruption, allowing co-delivery of siRNA against a non-druggable target. siRNA is encapsulated in lipid-stabilized, drug-rich colloidal nanoparticles where the ionizable lipid used in conventional lipid nanoparticles is replaced with an ionizable fulvestrant analog. The selection of an appropriate phospholipid and formulation buffer enables endocytosis and potent reporter gene knockdown in cancer cells. Importantly, siRNA targeting cyclin E1 is effectively delivered to drug-resistant breast cancer cells, demonstrating the utility of this approach. This strategy opens the possibility of using ionizable drugs to co-deliver RNA and ultimately improve therapeutic outcomes. https://lnkd.in/gkFfVPTA

Look out ADC therapies, there's a new cancer therapy on the block and it's less toxic than you :) Last week, after a year of operating in stealth mode, Firefly Bio, a Switzerland-based company emerged from stealth mode and announced $94M investment for development and scaling of a new class of antibody therapies, called degrader antibody conjugates (DAC) The therapies are the next generation of cancer immunotherapies that link protein degrading technology to antibodies, delivering antigen specific payloads into cancer cells without the toxicity issues of antibody drug conjugates (ADC). The star-studded team is made up of industry experts in the ADC space, including leaders from Genentech, AbbVie, and Merck. The ADC Nobel Laureate, Carolyn Bertozzi (known for her work on Click chemistry) is also involved in the company. The company’s lead therapeutic candidate focuses on targeting solid tumors in which standard ADC therapies have had dose-limiting toxicities that could benefit from a modified approach. (Enter DAC) Similar initiatives have recently been pursued in partnerships between Merck and C4 Therapeutics, as well collaborations between Pfizer and Nurix Therapeutics. Sources: FierceBiotech 👉Learn more about DAC technology in the comments #biotech #pharma #cancer

📢 Exciting News! Our latest blog post dives into the future of Antibody-Drug Conjugates (ADCs), one of the most promising advancements in targeted cancer therapy. ADCs combine the precision of monoclonal antibodies with the potency of chemotherapy, delivering drugs directly to cancer cells while minimizing damage to healthy tissue. The global market for ADCs is projected to skyrocket from $10.8 billion in 2023 to an impressive $47.0 billion by 2029, growing at a CAGR of 28.4%. The increasing need for effective cancer treatments and advanced ADC technologies drives this surge. Want to know more about how ADCs are revolutionizing oncology and what the future holds for this booming market? Check out our full analysis for key trends, growth drivers, and forecasts over the next five years. 🌱 https://bit.ly/3YjlxIk #AntibodyDrugConjugates #ADCTherapy #CancerTreatment #Biopharma #PharmaTrends #HealthcareInnovation #GlobalMarkets

Meet our CDO Christine Rothe and Jonas Schilz, Group Leader Antibody Discovery and Protein Interactions of iOmx, at the Festival of Biologics from October 15-17, 2024, in Basel.   Join Christine’s presentation on October 16th at 14:20 CET in the Targeting Checkpoint Pathways track as she dives into the science behind IOMX-0675, our cross-specific antibody that targets LILRB1 and LILRB2. This antibody is engineered to effectively repolarize the tumor microenvironment by antagonizing these two immuno-suppressive receptors while sparing the immuno-activating family members. The result is enhanced myeloid and lymphoid cell activation, leading to potent tumor cell destruction.   Take part in shaping the future of biologics for the treatment of cancer!   #CancerResearch #Immunotherapy #ImmunoOncology #TumorMicroenvironment #Biologics #FestivalOfBiologics